Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: bezafibrate SR + diflunisal IR; CRx-401; Diflunisal/bezafibrate

Latest Information Update: 29 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CombinatoRx
  • Developer Zalicus
  • Class Antihyperlipidaemics; Antirheumatics; Butyrates; Fibric acid derivatives; Nonsteroidal anti-inflammatories; Salicylates
  • Mechanism of Action Cyclooxygenase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 31 Dec 2010 Discontinued - Phase-II for Type-2 diabetes mellitus in Canada (PO)
  • 09 Sep 2010 CombinatoRx is now called Zalicus
  • 28 May 2009 Efficacy & adverse events data from a phase IIa trial in Type-2 diabetes released by CombinatoRx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top